Omthera trials fish oil pill Epanova with statins, hoping for 2012 filing in high TG
This article was originally published in Scrip
Omthera Pharmaceuticals continues to be optimistic that it is on track to file an NDA in 2012 with the US FDA for its prescription-grade omega-3 fatty acid candidate, Epanova, a novel formulation of free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for treating patients with very high triglyceride levels (500mg/dL and above) – based on the EVOLVE trial. That pivotal Phase III trial is being conducted under a special protocol assessment (SPA) with the FDA, which outlines an agreed-upon trial protocol design, and top-line results are expected in the first half of 2012.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.